IMI’s INNODIA project has added significantly to our understanding of type 1 diabetes (T1D). The aim of INNODIA HARVEST is to build on INNODIA’s results by carrying out additional activities that will further pave the way for new treatments to treat or even prevent T1D.
INNODIA HARVEST plans to consolidate the INNODIA clinical network and use it to run two clinical trials of drugs designed to stop T1D. One trial is driven by academia and focuses on the pancreatic beta cells, which are responsible for producing the hormone insulin. The other trial is industry driven and focuses on the role of the immune system (as the immune system attacks the beta cells in T1D).
Elsewhere, INNODIA HARVEST will continue INNODIA’s hunt for new biomarkers that could be used to track the progress of the disease, and implement new drug discovery pipelines for novel treatments for T1D
As in INNODIA, people with T1D and their families will be at the heart of the project to ensure the work meets their needs.